Charles River Laboratories and Synthace have announced a partnership to advance assay development by combining software, automation, and experimental design. This collaboration aims to make assay development faster, more efficient, and improve reproducibility, addressing a critical challenge in biological research that costs the industry billions annually. The initiative, revealed at SLAS 2026, focuses on High Dimensional Experimentation to overcome traditional bottlenecks and meet the demands of computational biology and AI in drug discovery.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Charles River and Synthace announce partnership for assay development
Charles River Laboratories and Synthace have announced a partnership to advance assay development by combining software, automation, and experimental design. This collaboration aims to make assay development faster, more efficient, and improve reproducibility, addressing a critical challenge in biological research that costs the industry billions annually. The initiative, revealed at SLAS 2026, focuses on High Dimensional Experimentation to overcome traditional bottlenecks and meet the demands of computational biology and AI in drug discovery.